Markets:

Overview

News

Currencies

International

Treasuries

Corvus Pharmaceuticals, Inc. - Common Stock (NQ:CRVS)

15.01 +0.04 (+0.23%)

Streaming Delayed Price Updated: 11:13 AM EDT, Jul 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Corvus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy? ↗

June 23, 2026

Immuno-oncology specialist Corvus Pharmaceuticals reported a recent insider buy amid a year of sharp share price gains.

Via The Motley Fool

Topics Regulatory Compliance

Adams Street Partners Exits Its 223,000-Share Paymentus (PAY) Position for $5.9 Million ↗

May 24, 2026

This cloud-based payments provider delivers SaaS solutions to enterprise billers across utilities, finance, and healthcare sectors.

Via The Motley Fool

Topics Regulatory Compliance

Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase ↗

May 17, 2026

Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.

Via The Motley Fool

Topics Regulatory Compliance

Corvus Pharmaceuticals Reports Q1 2026 Results; Atopic Dermatitis Program Takes Center Stage (NASDAQ:CRVS) ↗

May 07, 2026

Via Chartmill

Corvus Pharmaceuticals (NASDAQ:CRVS) Reports Q4 Earnings Miss Amid Positive Pipeline Data ↗

March 12, 2026

Via Chartmill

Topics Earnings

Why Is CRVS Stock Rising Today? ↗

January 20, 2026

Via Stocktwits

Corvus (CRVS) Q4 2025 Earnings Call Transcript ↗

March 12, 2026

Corvus (CRVS) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026 ↗

February 02, 2026

Via MarketBeat

CRVS Stock Surges Pre-Market After Corvus Expands Equity Raise To $175 Million ↗

January 22, 2026

Corvus increased its public stock offering to $175 million from $150 million, making 7.9 million shares of its common stock available for purchase at Wednesday’s closing price of $22.15.

Via Stocktwits

Dow, Nasdaq, S&P 500 Futures Tick Higher After Wall Street’s Worst Day In 3 Months: Why NFLX, AAPL, CRVS, GME, UAL Are In Focus Today ↗

January 20, 2026

Via Stocktwits

Topics Stocks

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Corvus Pharma Stock Dips Over 6% After-Hours Following Best Day Ever — What Went Wrong? ↗

January 20, 2026

The update follows the company’s release of cohort 4 data from its atopic dermatitis study of Soquelitinib.

Via Stocktwits

Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data ↗

January 20, 2026

Early eczema trial success and heavy trading are rapidly reshaping how investors view this drug developer, today, Jan. 20, 2026.

Via The Motley Fool

Topics Stocks

Here are the top movers in Tuesday's session. ↗

January 20, 2026

Via Chartmill

Tuesday's session: top gainers and losers ↗

January 20, 2026

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

January 20, 2026

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

January 20, 2026

Via Chartmill

Corvus Pharmaceuticals Inc (NASDAQ:CRVS) Reports Narrower-Than-Expected Q2 2025 Loss, Shares Rise on Clinical Progress ↗

August 07, 2025

Corvus Pharmaceuticals reported a narrower Q2 2025 loss of $0.10 per share, beating estimates, with shares rising 5.8% after-hours. Positive Phase 1 data for soquelitinib in atopic dermatitis boosted...

Via Chartmill

Corvus (CRVS) Q2 Loss Beats Estimates ↗

August 07, 2025

Via The Motley Fool

Topics Intellectual Property

12 Health Care Stocks Moving In Friday's Intraday Session ↗

May 09, 2025

Via Benzinga

Corvus Gets Price Target Hike From Oppenheimer On Positive Drug Trial Results: Retail’s Pleased ↗

May 09, 2025

Corvus announced new interim data from its Phase 1 clinical trial evaluating Soquelitinib in patients with moderate to severe atopic dermatitis.

Via Stocktwits

Why Is Corvus Pharmaceuticals Stock Soaring On Friday? ↗

May 09, 2025

Corvus Pharmaceuticals, Inc.(NASDAQ:CRVS) on Thursday released new interim data from the Phase 1 clinical trial evaluating ...

Via Benzinga

Wondering what's happening in today's pre-market session? ↗

May 09, 2025

Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 09, 2025

Via Benzinga

Why Pinterest Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket ↗

May 09, 2025

Via Benzinga

Curious about the stocks that are showing activity after the closing bell on Thursday? ↗

May 08, 2025

Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 08, 2025

Via Benzinga

These stocks are gapping in today's session ↗

March 26, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Wednesday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.